Catalyst Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference
Get Alerts CBIO Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 73.3%
EPS Growth %: +48.0%
Join SI Premium – FREE
SOUTH SAN FRANCISCO, Calif., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq: CBIO) today announced that Nassim Usman, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2017 Healthcare Conference being held in New York City. The Catalyst Biosciences presentation will be held on Tuesday, September 26, 2017 at 3:30 p.m. Eastern Time.
About Catalyst Catalyst is a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit www.catalystbiosciences.com.
Contacts: Investors: Fletcher Payne, CFO, Catalyst Biosciences 650.871.0761 [email protected] Media: Denise Powell 510.703.9491 [email protected]Source: Catalyst Biosciences, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 6 Best Crypto Presales as Bitcoin Heads for Its Strongest August Since 2017 and Remittix Nears a Major Milestone
- Faraday Future Advances Its “Built in USA” Strategy, Participates in the FCC’s Public-Comment Process, and Signs a U.S. Compliance and Localization Advisory Agreement with AIBOT
- Hyundai Mobis Accelerates Electrification Push in Europe with Opening of New Plant in Slovakia
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Ladenburg Thalmann Financial ServicesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share